Ascendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. Cantor Fitzgerald currently has a $170.00 price objective on the biotechnology company’s stock. Other analysts also recently issued research reports about the stock. StockNews.com upgraded shares of Ascendis […]
Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. Cantor Fitzgerald currently has a $170.00 price objective on the biotechnology company’s stock. Other analysts also recently issued research reports about the stock. StockNews.com upgraded shares of Ascendis […]
